Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) Program in the U.S.

[Business Wire] – Bristol-Myers Squibb Company today announced the establishment of the Immuno-Oncology Rare Population Malignancy program in the U.S. The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused . . . → Read More: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) Program in the U.S. Similar Articles: Market Update (NYSE:BMY): Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen Stock Update (NYSE:BMY): Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference Market Update (NYSE:BMY): Bristol-Myers Squibb Announces Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities